Retro Biosciences Company Profile

Background

Overview

Retro Biosciences is a biotechnology company founded in 2021, headquartered in Redwood City, California. The company is dedicated to developing therapies that address age-related diseases, aiming to extend healthy human lifespan by targeting the cellular mechanisms underlying aging.

Mission and Vision

Retro Biosciences' mission is to add 10 years to healthy human lifespan by developing therapeutics that prevent and reverse age-related diseases. The company's vision is to become a generational pharmaceutical company, addressing the scale of aging-related health challenges through innovative biotechnology solutions.

Primary Area of Focus

The company's primary focus is on cellular reprogramming, autophagy, and plasma-inspired therapeutics. By targeting the cellular drivers of aging, Retro Biosciences aims to develop multi-disease prevention strategies that can significantly improve human health and vitality.

Industry Significance

Retro Biosciences operates within the biotechnology sector, specifically focusing on aging and longevity. The company is part of a growing field that seeks to understand and intervene in the biological processes of aging, with the potential to revolutionize healthcare by addressing the root causes of age-related diseases.

Key Strategic Focus

Core Objectives

Retro Biosciences aims to develop therapies that meaningfully reverse age-related diseases, focusing on extending healthy human lifespan by targeting the cellular mechanisms of aging.

Specific Areas of Specialization

Cellular Reprogramming: Developing methods to rejuvenate cells and tissues by reprogramming their identity, potentially reversing age-related decline.

Autophagy: Enhancing the body's natural process of cleaning out damaged cells, which is crucial for maintaining cellular health and function.

Plasma-Inspired Therapeutics: Investigating the therapeutic potential of plasma-derived factors to promote tissue regeneration and combat aging.

Key Technologies Utilized

Single-Cell Multi-Omics: Employing advanced techniques to analyze gene expression, epigenetic modifications, and protein interactions at the single-cell level.

Pooled Perturbations: Utilizing pooled genetic perturbation screens to identify and validate therapeutic targets.

Targeted Delivery Systems: Developing systems to deliver therapeutic agents specifically to target cells or tissues, enhancing efficacy and reducing side effects.

Primary Markets or Conditions Targeted

Retro Biosciences focuses on age-related diseases, including neurodegenerative disorders, cardiovascular diseases, and metabolic conditions, aiming to prevent and reverse these conditions by addressing their underlying cellular causes.

Financials and Funding

Funding History

Retro Biosciences has raised a total of $180 million in funding. The most recent funding round was an angel investment in May 2022, led by Sam Altman, CEO of OpenAI.

Total Funds Raised

The company has secured a total of $180 million in funding to date.

Notable Investors

Sam Altman, CEO of OpenAI, is a notable investor in Retro Biosciences.

Intended Utilization of Capital

The capital raised is intended to support the development of Retro Biosciences' therapeutic programs, including advancing their pipeline candidates through preclinical and clinical stages, as well as expanding their research and development capabilities.

Pipeline Development

Key Pipeline Candidates

Retro Biosciences is developing several therapeutic programs targeting age-related diseases. Specific details about these pipeline candidates are not publicly disclosed.

Stages of Clinical Trials or Product Development

The company has achieved its First In Human milestone, officially entering the clinical stage.

Target Conditions

Retro Biosciences targets age-related diseases, including neurodegenerative disorders, cardiovascular diseases, and metabolic conditions.

Relevant Timelines for Anticipated Milestones

Specific timelines for upcoming milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

Cellular Reprogramming Techniques: Developing methods to rejuvenate cells and tissues by reprogramming their identity.

Autophagy Modulation: Enhancing the body's natural process of cleaning out damaged cells.

Plasma-Derived Therapeutics: Investigating the therapeutic potential of plasma-derived factors.

Significant Scientific Methods

Single-Cell Multi-Omics: Analyzing gene expression, epigenetic modifications, and protein interactions at the single-cell level.

Pooled Genetic Perturbation Screens: Identifying and validating therapeutic targets.

Targeted Delivery Systems: Delivering therapeutic agents specifically to target cells or tissues.

AI-Driven Capabilities

Retro Biosciences collaborates with OpenAI to redesign transcription factors using GPT-4 language models, achieving a 50-fold improvement in pluripotency marker expression and increasing reprogramming efficiency from 1% to potentially 50%.